- Conditions
- HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification, Colorectal Cancer
- Interventions
- ELVN-002, Trastuzumab, 5-Fluorouracil, Oxaliplatin, Capecitabine, Eribulin, paclitaxel, Leucovorin
- Drug
- Lead sponsor
- Enliven Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 3
- States / cities
- Plantation, Florida • St Louis, Missouri • Fairfax, Virginia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 5,450
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms
- Interventions
- LOXO-260
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 14
- States / cities
- Los Angeles, California • San Francisco, California • Atlanta, Georgia + 10 more
- Conditions
- Advanced Cancer
- Interventions
- BMS-986310, Nivolumab
- Drug · Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 4
- States / cities
- St Louis, Missouri • Hackensack, New Jersey • Pittsburgh, Pennsylvania + 1 more
- Conditions
- Neoplasms, Carcinoma, Non-Small-Cell Lung
- Interventions
- Ezabenlimab, BI 754111
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 6
- States / cities
- Miami, Florida • Sarasota, Florida • Hackensack, New Jersey + 3 more
- Conditions
- Cancer
- Interventions
- Nivolumab, Cabiralizumab, Urelumab, Stereotactic Body Radiation Therapy
- Drug · Radiation
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment
- Interventions
- 145 mg/m2 NKTR 102, 120 mg/m2 NKTR 102, 50 mg/m2 NKTR 102
- Drug
- Lead sponsor
- Nektar Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 3
- States / cities
- Los Angeles, California • San Francisco, California • Cleveland, Ohio
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- MRG004A
- Drug
- Lead sponsor
- Lepu Biopharma Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 6
- States / cities
- Orange, California • New York, New York • Canton, Ohio + 3 more
- Conditions
- Solid Tumor
- Interventions
- ORIC-101, Nab-paclitaxel
- Drug
- Lead sponsor
- ORIC Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 12
- States / cities
- Palo Alto, California • San Francisco, California • Aurora, Colorado + 9 more
- Conditions
- Solid Tumours
- Interventions
- ODM-212
- Drug
- Lead sponsor
- Orion Corporation, Orion Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Orange, California • St Louis, Missouri + 5 more
- Conditions
- Solid Tumors, KRAS Mutation; SOS1
- Interventions
- BI 1701963, Trametinib
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Charlotte, North Carolina • Nashville, Tennessee + 1 more
- Conditions
- Advanced Solid Tumors
- Interventions
- MNK-010
- Drug
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
- Interventions
- Educational Intervention, Internet-Based Intervention, Interview, Patient Navigation, Survey Administration, Telephone-Based Intervention, Text Message-Based Navigation Intervention
- Other · Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 578 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2032
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Advanced Solid Tumor
- Interventions
- BG-75098, BGB-43395, Fulvestrant
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Duarte, California • New Haven, Connecticut + 4 more
- Conditions
- Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor, Microsatellite Stable (MSS) Colon Cancer
- Interventions
- Copanlisib, Nivolumab
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Advanced Pancreatic Cancer, Solid Tumor Malignancies
- Interventions
- ProAgio Dose Levels (DL) 1,2,3, ProAgio Dose Levels (DL) 4,5,6, ProAgio Dose Levels 4a,5a,6a
- Drug
- Lead sponsor
- ProDa BioTech, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Solid Tumors, Metastatic Solid Tumors
- Interventions
- DS3610a
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Adult Solid Neoplasm, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier
- Interventions
- Diagnostic Laboratory Biomarker Analysis, Gemcitabine Hydrochloride, Pharmacological Study, Veliparib
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 4
- States / cities
- Hershey, Pennsylvania • Pittsburgh, Pennsylvania
- Conditions
- Advanced Solid Tumor, Soft Tissue Sarcoma Adult
- Interventions
- SON-1010
- Biological
- Lead sponsor
- Sonnet BioTherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Advanced Solid Malignancies
- Interventions
- CT7001, Fulvestrant
- Drug
- Lead sponsor
- Carrick Therapeutics Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 12
- States / cities
- Tucson, Arizona • Beverly Hills, California • Tampa, Florida + 9 more
- Conditions
- Advanced Solid Tumor
- Interventions
- Ramucirumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 4
- States / cities
- Fayetteville, Arkansas • Omaha, Nebraska • Charlotte, North Carolina + 1 more
- Conditions
- Malignant Solid Tumor, Lymphoma
- Interventions
- RRx-001, Nivolumab
- Drug
- Lead sponsor
- EpicentRx, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Advanced Solid Tumor
- Interventions
- OBI-902
- Drug
- Lead sponsor
- OBI Pharma, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 3
- States / cities
- La Jolla, California • Houston, Texas • San Antonio, Texas
- Conditions
- Malignant Germ Cell Tumor, Lung Adenocarcinoma, Gastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma, Urothelial Carcinoma, Endometrial Adenocarcinoma, Ovarian Adenocarcinoma
- Interventions
- DBC-664
- Biological
- Lead sponsor
- Duboce Biopharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 6
- States / cities
- Denver, Colorado • Grand Rapids, Michigan • East Brunswick, New Jersey + 3 more
- Conditions
- Advanced Solid Tumor, Non Small Cell Lung Cancer Metastatic
- Interventions
- DRP-104, atezolizumab
- Drug · Biological
- Lead sponsor
- Dracen Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 13
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Kissimmee, Florida + 8 more